- US-listed companies
- NOVARTIS AG
- Cash flow
NOVARTIS AG (NVS) Cash flow
Market cap
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Cash from operations | 14,272 | 13,625 | 13,650 | 15,071 | 14,236 | 14,458 | 17,619 | 19,144 |
| Capital expenditures | -1,773 | -1,379 | -1,275 | -1,378 | -1,198 | -1,060 | -1,366 | -1,548 |
| Cash from investing | -5,591 | -2,226 | -13,182 | 4,208 | 1,468 | 5,596 | -7,513 | -4,877 |
| Repurchases of common stock | 2,036 | 5,533 | 2,842 | 3,057 | 10,652 | 8,719 | 8,331 | 9,212 |
| Proceeds from issuance of term debt, net | 2,856 | 93 | 7,126 | 16 | 16 | - | 6,143 | 6,098 |
| Repayments of term debt | 366 | 3,195 | 2,003 | 2,162 | 2,575 | 2,223 | 2,160 | 3,392 |
| Cash from financing | -4,244 | -13,627 | -2,208 | -16,264 | -20,562 | -14,278 | -11,742 | -14,867 |
| Free cash flow | ||||||||
| FCF margin (%) |